Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2022-03-07 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 99% confidence The document is identified by the RNS Number header and explicitly states it concerns 'Transactions by Persons Discharging Managerial Responsibilities (PDMRs)' regarding the granting of share awards to executives (Pascal Soriot and Aradhana Sarin). This type of filing, detailing personal share transactions by company directors and executives, directly matches the definition for Director's Dealing (DIRS). Although it references the Annual Report for performance details, the core content is the insider transaction disclosure, which is a specific regulatory requirement.
2022-03-07 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a transaction involving shares held by a director (Dr Aradhana Sarin, CFO). The content details the vesting of restricted stock awards and the acquisition of American Depositary Shares by a person discharging managerial responsibilities. This is a notification of insider share transactions by a company director. The document does not contain financial statements or earnings data, nor is it an announcement of a report or a general regulatory filing. It specifically reports a director's dealing in company shares, consistent with insider trading disclosures. Therefore, the appropriate classification is Director's Dealing (DIRS). The document length and detail support a high confidence in this classification.
2022-03-01 English
TOTAL VOTING RIGHTS
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on the total voting rights as of a specific date, providing details about the issued share capital and voting rights. It references the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1, indicating it is a regulatory disclosure about voting rights rather than a full report or financial statement. The document length is 3174 characters, which is relatively short and primarily serves as a notification of voting rights rather than a detailed report. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like Annual Report, Earnings Release, or Voting Results. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-03-01 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official notification disseminated via RNS (RNS Number: 2402D) dated March 1, 2022. The content explicitly details a 'Transaction by Person Discharging Managerial Responsibilities' (Dr Aradhana Sarin, CFO) concerning the vesting and acquisition of AstraZeneca American Depositary Shares (ADSs) under a stock plan. This type of filing, reporting personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing. The structure and content match the requirements for reporting insider trades under MAR regulations, which is explicitly mentioned ('EU Market Abuse Regulation'). Therefore, the classification is DIRS.
2022-03-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details the total number of voting rights and issued share capital as of a specific date (28 February 2022), referencing the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of mandatory, periodic disclosure regarding voting rights and capital structure is a standard regulatory announcement. Since there is a specific category for general regulatory announcements that don't fit elsewhere, and this is a direct regulatory update, it fits best under the general Regulatory Filings category (RNS), although it is closely related to share capital changes. Given the context of RNS distribution and the nature of the disclosure (voting rights denominator), RNS is the most appropriate general classification, as 'SHA' (Share Issue/Capital Change) is usually for active changes, not periodic reporting of the total count.
2022-03-01 English
ASTRAZENECA AND NEURIMMUNE CLOSE DEAL FOR NI006
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. It announces the closing of a deal between AstraZeneca and Neurimmune for the development and commercialization of NI006, including financial terms and background information on the drug and disease. The document does not contain comprehensive financial statements or detailed financial performance data. It is primarily an announcement of a corporate collaboration and licensing agreement. Form 6-K filings are typically used for current reports by foreign private issuers and are considered regulatory filings. Therefore, this document fits best under the category of Regulatory Filings (RNS). The document length (7758 characters) and content confirm it is not a full annual or interim report, nor a presentation or earnings release. Confidence in this classification is high due to the clear identification of the form type and content.
2022-03-01 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.